Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Sørrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P.

Eur J Haematol. 2019 Feb;102(2):182-190. doi: 10.1111/ejh.13190. Epub 2018 Nov 28.

PMID:
30485563
2.

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.

Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Frølund UC, Gimsing P, Helleberg C, Vangsted AJ.

Leukemia. 2019 Feb;33(2):546-549. doi: 10.1038/s41375-018-0272-0. Epub 2018 Sep 28. No abstract available.

PMID:
30267010
3.

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25134. [Epub ahead of print]

4.

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.

Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C, Dissing Sjö L, Ralfkiaer E, Gimsing P, Grønbaek K.

Leuk Lymphoma. 2019 Jan;60(1):180-188. doi: 10.1080/10428194.2018.1466290. Epub 2018 May 2.

PMID:
29718735
5.

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted AJ, Frølund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H.

Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19.

6.

Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark.

Sørrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P.

Eur J Haematol. 2018 Jul;101(1):21-27. doi: 10.1111/ejh.13066. Epub 2018 May 4.

PMID:
29569379
7.

Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.

Helm-Petersen S, Sørrig R, Klausen TW, Preiss B, Frølund UC, Helleberg C, Breinholt M, Andersen MK, Abildgaard N, Gimsing P, Vangsted AJ.

Leukemia. 2018 Sep;32(9):2054-2057. doi: 10.1038/s41375-018-0057-5. Epub 2018 Feb 22. No abstract available.

PMID:
29500392
8.

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Frølund UC, Andersen KT, Klostergaard A, Helleberg C, Pedersen RS, Pedersen PT, Helm-Petersen S, Teodorescu EM, Preiss B, Abildgaard N, Gimsing P; Danish Myeloma Study Group.

PLoS One. 2017 Dec 7;12(12):e0188988. doi: 10.1371/journal.pone.0188988. eCollection 2017.

9.

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.

Dimopoulos K, Søgaard Helbo A, Fibiger Munch-Petersen H, Sjö L, Christensen J, Sommer Kristensen L, Asmar F, Hermansen NEU, O'Connel C, Gimsing P, Liang G, Grønbaek K.

Mol Oncol. 2018 Feb;12(2):180-195. doi: 10.1002/1878-0261.12157. Epub 2017 Dec 30.

10.

Drug response prediction in high-risk multiple myeloma.

Vangsted AJ, Helm-Petersen S, Cowland JB, Jensen PB, Gimsing P, Barlogie B, Knudsen S.

Gene. 2018 Feb 20;644:80-86. doi: 10.1016/j.gene.2017.10.071. Epub 2017 Nov 6.

PMID:
29122646
11.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.

12.

Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.

Thidemann Andersen K, Klausen T, Abildgaard N, Klarskov Andersen M, Frost Andersen N, Christian Frølund U, Helleberg C, Kjeldsen E, Pedersen P, Helm-Petersen S, Svirskaite A, Preiss B, Gimsing P, Juul Vangsted A.

Am J Hematol. 2017 Oct;92(10):E611-E614. doi: 10.1002/ajh.24857. Epub 2017 Aug 17. No abstract available.

13.

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.

Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frølund UC, Helleberg C, Broch B, Pedersen PT, Gimsing P, Klausen TW.

Cancer Med. 2017 Jul;6(7):1807-1816. doi: 10.1002/cam4.1128. Epub 2017 Jun 22.

14.

The Danish National Multiple Myeloma Registry.

Gimsing P, Holmström MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frølund U, Helleberg C, Vangsted A, de Nully Brown P, Abildgaard N.

Clin Epidemiol. 2016 Oct 25;8:583-587. eCollection 2016. Review.

15.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

16.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

17.

Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.

Hermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P.

Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29.

PMID:
27027250
18.

Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.

Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Østergaard B, Gregersen H, Frølund UC, Andersen NF, Helleberg C, Andersen KT, Pedersen RS, Pedersen P, Abildgaard N, Gimsing P; Danish Myeloma Study Group.

Eur J Haematol. 2016 Sep;97(3):303-9. doi: 10.1111/ejh.12728. Epub 2016 Feb 5.

PMID:
26710662
19.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

20.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG.

N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.

21.

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.

22.

N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.

Mylin AK, Goetze JP, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P; Nordic Myeloma Study Group.

Biomark Med. 2015;9(7):679-89. doi: 10.2217/bmm.15.35.

PMID:
26174842
23.

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S.

Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29.

24.

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A.

Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.

25.

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.

Hansson M, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G.

Clin Cancer Res. 2015 Jun 15;21(12):2730-6. doi: 10.1158/1078-0432.CCR-14-3090. Epub 2015 Feb 24.

26.

Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; Nordic Myeloma Study Group.

Leuk Lymphoma. 2015;56(9):2650-9. doi: 10.3109/10428194.2015.1004168. Epub 2015 Feb 11.

PMID:
25573204
27.

Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.

Holmström MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, Klausen TW, Frederiksen M, Kristensen DL, Larsen H, Pedersen PT, Andersen KT, Pedersen RS, Jensen BA, Gregersen H, Vangsted AJ.

Am J Hematol. 2015 Apr;90(4):E73-4. doi: 10.1002/ajh.23932. Epub 2015 Feb 2. No abstract available.

28.

Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.

Nelson LM, Gustafsson F, Gimsing P.

Acta Haematol. 2015;133(4):336-46. doi: 10.1159/000363682. Epub 2014 Dec 16.

PMID:
25531398
29.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25242045
30.

Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.

Eur J Haematol. 2015 Jan;94(1):60-6. doi: 10.1111/ejh.12401. Epub 2014 Jul 16.

PMID:
24954766
31.

The role of epigenetics in the biology of multiple myeloma.

Dimopoulos K, Gimsing P, Grønbæk K.

Blood Cancer J. 2014 May 2;4:e207. doi: 10.1038/bcj.2014.29. Review.

32.

Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmström M, Gregersen H, Vogel U, Schwarz P, Jørgensen NR.

Eur J Haematol. 2014 Aug;93(2):172-4. doi: 10.1111/ejh.12353. Epub 2014 May 17. No abstract available.

PMID:
24766221
33.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

34.

Primary localised cutaneous amyloidosis--a systematic review.

Kaltoft B, Schmidt G, Lauritzen AF, Gimsing P.

Dan Med J. 2013 Nov;60(11):A4727. Review.

PMID:
24192243
35.

Multiple myeloma in a kidney transplanted patient primarily diagnosed with monoclonal gammopathy of unknown significance (MGUS)-related nephropathy.

Resuli M, Nielsen FT, Gimsing P, Andersen CB, Egfjord M.

Clin Kidney J. 2013 Aug;6(4):445-6. doi: 10.1093/ckj/sft060. Epub 2013 Jul 2. No abstract available.

36.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

37.

Aberrant microRNA expression in multiple myeloma.

Dimopoulos K, Gimsing P, Grønbæk K.

Eur J Haematol. 2013 Aug;91(2):95-105. doi: 10.1111/ejh.12124. Epub 2013 Jun 5. Review.

PMID:
23586898
38.

CD138+ cell separation affects cancer gene expression in human myeloma cell lines.

Sørrig R, Hermansen NE, Hother C, Gimsing P.

Eur J Haematol. 2013 Aug;91(2):187-8. doi: 10.1111/ejh.12120. Epub 2013 Jun 5. No abstract available.

PMID:
23581887
39.

[The Haematological Corporate Database].

Brown Pde N, Nørgaard JM, Gimsing P, Hasselbalch H, Abildgård N, Jensen P, Bukh A.

Ugeskr Laeger. 2012 Oct 15;174(42):2526. Danish. No abstract available.

PMID:
23079429
40.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P.

Haematologica. 2013 Jan;98(1):87-94. doi: 10.3324/haematol.2012.067058. Epub 2012 Aug 8.

41.

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30.

42.

[Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].

Mellstedt H, Gimsing P, Waage A.

Lakartidningen. 2011 Oct 19-25;108(42):2090-4. Review. Swedish. No abstract available.

PMID:
22165535
43.

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.

Int J Cancer. 2012 Sep 1;131(5):E636-42. doi: 10.1002/ijc.27387. Epub 2012 Jan 31.

44.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P.

Blood. 2011 Oct 27;118(17):4519-29. doi: 10.1182/blood-2011-06-358812. Epub 2011 Aug 12. Review.

45.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network.

Blood. 2011 Aug 4;118(5):1239-47. doi: 10.1182/blood-2011-03-341669. Epub 2011 Jun 13.

46.

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U.

Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24.

PMID:
21347685
47.

The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø BA, Vogel UB.

Ann Hematol. 2011 Jun;90(6):675-84. doi: 10.1007/s00277-010-1105-z. Epub 2010 Nov 3.

PMID:
21046104
48.

Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.

Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM.

Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x.

49.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F.

Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4.

PMID:
20863761
50.

Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.

Johnsen HE, Klausen TW, Boegsted M, Lenhoff S, Gimsing P, Christiansen I, Gedde-Dahl T, Lindås R, Mellqvist UH; Nordic Myeloma Study Group.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):290-6. doi: 10.3816/CLML.2010.n.060.

PMID:
20709667

Supplemental Content

Loading ...
Support Center